{"id":30132,"date":"2026-07-02T21:00:00","date_gmt":"2026-07-02T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=b9143a16811bbebad61dd76daae4ced6"},"modified":"2026-07-02T21:00:00","modified_gmt":"2026-07-02T19:00:00","slug":"theraclion-monthly-information-on-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=30132","title":{"rendered":"Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital"},"content":{"rendered":"

\nArticle 223-16 - R\u00e8glement G\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiers<\/p>

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:<\/p>

\nTheraclion (Paris:ALTHE):<\/p>

\nListed on Euronext Growth Paris\nPEA PME eligible\nISIN Code: FR0010120402\nWebsite: www.theraclion.com<\/a><\/p>

\nVoting rights:<\/b><\/p>\n\n\n

\nDate<\/b><\/p><\/td>

\nTotal number of shares of Theraclion<\/b><\/p><\/td>

\nTotal number of theoretical voting rights of Theraclion (1)<\/sup><\/b><\/p><\/td>

\nTotal number of real voting rights of Theraclion (2)<\/sup><\/b><\/p><\/td><\/tr>\n

\n30\/06\/2026<\/p><\/td>

\n73 123 311<\/p><\/td>

\n89 137 355<\/p><\/td>

\n87 570 061<\/p><\/td><\/tr>\n<\/table>

\n(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation<\/i><\/p>

\n(2) <\/i>Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.<\/i><\/p>

\nAbout Theraclion<\/b><\/p>

\nTheraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.\nHigh-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.\nTheraclion is developing Sonovein\u00ae, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017\/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein\u00ae has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein\u00ae is not yet available for sale.<\/p>

\nBased in Malakoff (Paris), the Theraclion team consists of approximately 35 people.<\/p>

\nFor more information, please visit <\/b>www.theraclion.com<\/b><\/a> and follow us on <\/b>LinkedIn<\/b><\/a>.<\/b><\/p>

\nTheraclion is listed on Euronext Growth Paris\nEligible for the PEA-PME scheme\nTicker: ALTHE - ISIN Code: FR0010120402\nLEI: 9695007X7HA7A1GCYD29<\/p> Contacts<\/b>

\nTheraclion<\/b>Martin Deterre\nChief Executive Officer\ncontact@theraclion.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Article 223-16 – R\u00e8glement G\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiersMALAKOFF, France–(BUSINESS WIRE)–Regulatory News:
\nTheraclion (Paris:ALTHE):
\nListed on Euronext Growth Paris
\nPEA PME eligible
\nISIN Code: FR0010120402
\nWebsite: www.theraclion.com
\nV…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-30132","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30132"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30132\/revisions"}],"predecessor-version":[{"id":30133,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30132\/revisions\/30133"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}